Smartkem Inc

This proposal asks stockholders to cast a non-binding advisory vote approving the Company’s executive compensation program for its named executive officers (a “Say-on-Pay” vote). Management frames the program as structured to attract, motivate, and retain executive talent while aligning pay with performance through a mix of base salary, bonuses, and equity awards described in the Proxy Statement. The Compensation Committee will use the outcome as input for future compensation decisions, though the vote is advisory and not binding. Contextually, SmartKem is a small public company with recent equity grants, one‑time bonuses granted in 2025, and employment agreements that include severance and change‑in‑control protections; these features make executive pay a material governance issue for investors. The Board recommends approval, asserting that the program supports corporate objectives and stockholder value; it emphasizes competitiveness and pay‑for‑performance design. Potential governance concerns for analysts include the magnitude and structure of equity grants, severance provisions (including increases to CEO severance), and the one‑time bonuses paid in 2025, which may raise sensitivity around timing and discretion. Analyzing this vote should weigh whether compensation incentives align management with long‑term value creation, whether pay is commensurate with company performance and peer practice, and whether disclosure provides sufficient detail on metrics and vesting. Given the Board’s affirmative recommendation and the Committee’s oversight, a “for” vote signals support for management’s compensation philosophy but does not limit future stockholder engagement or requests for enhanced disclosure or metric‑based targets.

This proposal asks stockholders to indicate their preferred frequency (one, two, or three years) for future non-binding advisory votes on executive compensation. Management and the Board recommend an annual vote, arguing that yearly disclosure and compensation decisions make annual feedback most appropriate for informing the Compensation Committee and aligning incentives. The advisory nature means the Board is not legally bound by the outcome but typically follows significant stockholder sentiment to maintain good governance and investor relations. For a governance analyst, the choice reflects tradeoffs between administrative burden and responsiveness: annual votes increase engagement and accountability but may encourage short‑term focus; multi‑year votes reduce administrative frequency but may reduce timely feedback. SmartKem’s Board emphasizes that annual Say‑on‑Pay votes allow investors to react to annual changes in pay and performance, especially relevant for a smaller company with active equity compensation programs and recent amendments to executive employment agreements. The Board’s recommendation for an annual vote highlights its preference to receive frequent stockholder input as compensation decisions are made annually and to ensure the Compensation Committee remains accountable. In evaluating the practical effect, consider whether management disclosure and metrics are sufficiently robust to make yearly assessments meaningful; if not, investors might favor a multi‑year cadence paired with enhanced disclosure. Overall, an annual advisory vote is intended to support dynamic governance oversight and ongoing investor engagement.

This proposal seeks shareholder approval to amend the Company’s certificate of incorporation to expand authorized common shares dramatically from 300 million to 5 billion (before any reverse split). Management says the purpose is to create capacity for future capital raises, employee and director equity grants, potential acquisitions, and strategic transactions without the delay of seeking additional shareholder approval for each use. The Board frames this as prudent flexibility, particularly given planned financing arrangements (including an Equity Line of Credit and recently issued convertible preferred stock and warrants) and the need to reserve large blocks of shares for conversion or issuance. A key governance consideration is that a very large authorized share count can be used defensively and could enable substantial dilution without further stockholder votes if the board exercises its authority; the Proxy discloses that management could use the additional shares to oppose hostile takeovers by selling stock to friendly parties. Analysts should weigh the company’s cash runway and capital needs against dilution risk: the amendment supports liquidity and equity‑based incentives but materially increases the company’s capacity to dilute current holders. The Board recommends a “for” vote, arguing benefits outweigh risks by facilitating timely financings and operational flexibility; however, investors should expect follow‑on issuances and analyze management’s capital allocation plans and governance safeguards. If approved, the amendment becomes effective upon filing with Delaware and will enable reserving shares for existing commitments (noted in the Proxy) and large future financings, so the near‑term practical effect could be a sizable increase in fully diluted share counts depending on management actions.

This proposal asks stockholders to approve an increase to the 2021 Equity Incentive Plan share reserve by 500,930 shares to ensure the Company can continue granting options, RSUs and other awards to employees, directors and consultants. Management asserts the increase is required to retain and motivate talent, to align long‑term incentives with stockholder value, and to permit grants that may qualify as incentive stock options under Section 422 of the Internal Revenue Code. The Board indicates this amendment is also intended to satisfy Nasdaq rules and provide flexibility for future hiring and retention needs as the Company scales. For governance analysis, the primary considerations are dilution, the pace and size of historical grants, and whether the company has adequate equity governance (e.g., grant policies, limits to director awards, and disclosure of expected usage). The Proxy discloses current outstanding awards and remaining availability, enabling assessment of burn rate and potential dilution; investors should compare the proposed increase to historical grant activity and peer practices. The Board recommends the amendment, arguing that without it the Company’s ability to make competitive equity grants would be constrained, potentially impairing recruitment and retention. Analysts should evaluate the expected timing and recipients of new awards, vesting terms, and whether performance conditions will be used to align with long‑term value creation. Overall, the amendment supports management’s human capital strategy but requires monitoring of issuance pace and its impact on future dilution.

This proposal asks shareholders to approve giving the Board discretionary authority to implement up to two reverse stock splits, each at a ratio between 1:2 and 1:125, with aggregate effect not to exceed 1:250, exercisable within a year of approval. Management’s stated objective is to increase the per‑share market price to make the stock more attractive to institutional investors, reduce volatility related to low‑priced trading, potentially meet Nasdaq minimum price requirements, and improve market perceptions and broker handling of the shares. The Board retains full discretion to implement, select the ratio and timing, or abandon the splits if conditions change, which provides operational flexibility but concentrates significant authority in management. Analysts should consider that while reverse splits can raise nominal share price, they do not change company fundamentals and can reduce float and liquidity; if the post‑split price fails to sustain, delisting risk remains. The Proxy cautions that reverse splits could be viewed negatively by some investors and that any decline in stock price post‑split could result in greater percentage declines. The Board recommends approval to preserve listing and strategic options, noting that without such authority the company might lack a timely tool to address Nasdaq compliance or investor access issues. For governance evaluation, it's important to review whether the Board has adequate guardrails (e.g., limits on aggregate ratio, timing windows) and to monitor subsequent communications around the rationale and intended ratio if implemented. Overall, the measure is a defensive and tactical governance tool aimed at addressing capital markets mechanics rather than underlying operations.

This proposal seeks shareholder approval under Nasdaq rules to permit the company to issue, at times, shares under the Equity Line Purchase Agreement in amounts exceeding 19.99% of outstanding stock for prices that may be below the Nasdaq 'Minimum Price.' Nasdaq Listing Rule 5635(d) requires such approval for issuances greater than 20% at below‑minimum pricing. The Company entered into an Equity Line Purchase Agreement with Keystone providing up to $500 million subject to limits, and management wants the flexibility to draw shares based on market VWAP‑based pricing (including potential sub‑Minimum Price issuance). If approved, the Equity Line would materially expand the Company’s access to capital and could be an efficient liquidity source; if not approved, the company may need alternative financing which could be more dilutive or expensive, potentially affecting operations and timelines. Key investor concerns include the potential for substantial dilution (magnitude depends on market prices at issuance), issuance at steep discounts to contemporaneous market prices, and concentration risk if a single counterparty acquires a large position. Management frames the approval as necessary to fully utilize a committed financing vehicle and to support business plans; the Board recommends approval for financial flexibility. Analysts should model potential dilution scenarios, consider covenant and anti‑dilution features, and evaluate whether pricing mechanics and caps are adequately disclosed and protective of current holders. The transaction's practical effect hinges on future drawdowns and market conditions, so ongoing transparency and use‑of‑proceeds disclosure will be important for investors.

This proposal asks shareholders to approve potential future issuances of common stock that could exceed 19.99% of outstanding shares at prices below the Nasdaq 'Minimum Price' in connection with the conversion terms of recently issued Series A convertible preferred stock and attendant warrants sold in a private placement. The Certificate of Designations sets an initial conversion price above the Minimum Price, but it also provides for alternative conversion or exercise prices under certain events that could fall below the Minimum Price, triggering Nasdaq Rule 5635(d) and the need for shareholder approval. Management indicates this approval is procedural to allow conversions or warrant exercises under contractual terms the Company agreed with investors; without approval, conversions or exercises that would otherwise breach the threshold would be constrained and the Company would need to seek repeat approvals to process these transactions, creating operational and financing frictions. Investors should focus on the potential dilution magnitude (the Proxy discloses the large number of shares issuable upon conversion and exercise), anti‑dilution protections in the warrant terms, and whether the conversion mechanics could concentrate ownership. The Board recommends approval to maintain contractual flexibility and avoid repeated shareholder votes; from a governance perspective, approval permits consummation of negotiated financing terms but increases issuance capacity tied to the private placement. Analysts should evaluate conversion scenarios, timing, and the interplay with other outstanding commitments (including the Equity Line) to quantify dilution and potential control implications. Overall, the proposal is intended to allow the company to implement previously negotiated financing instruments without undue procedural obstacles, while raising legitimate dilution and investor concentration considerations.

This proposal asks shareholders to approve an amendment to permit stockholders to act by written consent rather than requiring a meeting for certain actions, subject to DGCL and bylaw procedures. Management argues the change increases flexibility and efficiency, enabling prompt stockholder action without the logistical overhead of convening a meeting, which can be valuable for timely corporate responses or routine corporate business. The Board notes that any written consent would require the same vote threshold as the equivalent action at a meeting and that existing Delaware protections and bylaw procedures remain in force, aiming to balance convenience with safeguards. From a governance perspective, written consent can enhance minority stockholder access to effect change without relying on convening a full meeting, but it can also enable expedited action by a controlling block if procedural protections are absent. Analysts should review the Company’s bylaws and any special voting rights of preferred stock to assess whether appropriate notice and aggregation safeguards exist and to ensure the amendment is not coupled with other changes that could weaken stockholder protections. The Board recommends approval as consistent with improved stockholder engagement and streamlined corporate governance. If approved, the amendment aligns SmartKem with common practice among public companies, while the practical effect will depend on how the Board and stockholders use the written consent mechanism and any procedural limits the bylaws impose.

This proposal seeks approval to remove existing two‑thirds (66 2/3%) supermajority vote thresholds in the charter for certain corporate actions, thereby lowering the vote requirement to a majority consistent with DGCL default standards. Management contends the supermajority provisions are no longer necessary and can impede timely action by stockholders, including actions by written consent; removing them aligns the Company with prevailing governance norms and facilitates more efficient corporate decision‑making. For investors, this change reduces entrenchment risk and can make it easier for a simple majority of shares to effect corporate governance changes, potentially increasing accountability of the Board and management. However, some defensive provisions can offer stability against opportunistic transactions; analysts should evaluate whether the removal meaningfully changes takeover defenses or affects existing preferred stock rights. The Board recommends the amendment as balancing enhanced stockholder rights with existing legal protections and the terms of any outstanding preferred stock. Practically, the amendment could lower the barrier for corporate actions previously needing supermajority approval, increasing shareholder influence but also potentially reducing minority protections in certain scenarios. Investors should review the specific charter articles being amended to assess the precise corporate actions affected and monitor whether other charter or bylaw provisions retain any heightened thresholds.